Breaking News Instant updates and real-time market news.

CDK

CDK Global

$71.62

0.81 (1.14%)

, CG

Carlyle Group

$23.65

0.2 (0.85%)

08:52
02/15/18
02/15
08:52
02/15/18
08:52

Carlyle, Silver Lake no longer actively bidding for CDK, Dealreporter says

The valuation of CDK Global (CDK) is giving Carlyle Group (CG) and Silver Lake pause and the private equity consortium is no longer actively working on a CDK buyout, two sources told Dealreporter, according to contacts. If CDK revises its valuation expectations it is possible deal talks could be revived, the report added, according to contacts. Two other PE consortiums - Vista Equity Partners and Bain Capital and Thoma Bravo and Advent International - were no longer actively negotiating with CDK, Bloomberg has said and a source has corroborated to Dealreporter, according to its report.

CDK

CDK Global

$71.62

0.81 (1.14%)

CG

Carlyle Group

$23.65

0.2 (0.85%)

CDK CDK Global
$71.62

0.81 (1.14%)

10/31/17
BRRR
10/31/17
NO CHANGE
BRRR
CDK Global estimates raised after solid Q1 results at Barrington
Barrington analyst Gary Prestopino maintained an Outperform rating and $75 price target on CDK Global, and raised his FY18 adjusted EPS estimate to $2.95 from $2.90 following CDK Global's better than expected Q1 results, with Prestopino saying that CDK "continues to solidly execute on its transformation plan."
01/17/18
BRRR
01/17/18
DOWNGRADE
Target $75
BRRR
Market Perform
CDK Global downgraded to Market Perform from Outperform at Barrington
Barrington analyst Gary Prestopino downgraded CDK Global to Market Perform with an unchanged price target of $75.
01/17/18
BRRR
01/17/18
DOWNGRADE
Target $75
BRRR
Market Perform
CDK Global downgraded to Market Perform on valuation at Barrington
Barrington analyst Gary Prestopino downgraded CDK Global to Market Perform from Outperform citing valuation following the stock's recent rally. A financial buyer may not pay much more of a premium for the company, Prestopino tells investors in a research note, referencing media reports indicating CDK is exploring a sale. The analyst keeps a $75 price target for the shares.
01/31/18
WELS
01/31/18
NO CHANGE
Target $80
WELS
Outperform
CDK Global price target raised to $80 from $75 at Wells Fargo
Wells Fargo analyst Timothy Willi raised his price target for CDK Global to $80 from $75 following quarterly results. The analyst reiterates an Outperform rating on the shares.
CG Carlyle Group
$23.65

0.2 (0.85%)

11/14/17
OPCO
11/14/17
NO CHANGE
Target $40
OPCO
Outperform
Envision buyout price could approach $50 per share, says Oppenheimer
After Bloomberg reported that private equity firms Carlyle Group (CG) and Onex have shown interest, Oppenheimer analyst Michael Wiederhorn says he believes a buyout offer for Envision Healthcare could approach $50 per share. The stock in afternoon trading is up 8% to $27.96. Such an offer is based on an 11 times 2018 EBITDA estimate, which is multiple similar to the one paid by Blackstone (BX) for Team Health in late 2016, Wiederhorn tells investors in a research note. The analyst believes Envision has a "strong growth business" and he recommends continuing to buy the shares at current levels. Wiederhorn has an Outperform rating on Envision with a $40 price target.
12/04/17
MSCO
12/04/17
NO CHANGE
Target $28
MSCO
Overweight
Carlyle Group recent weakness a buying opportunity, says Morgan Stanley
Morgan Stanley analyst Michael Cyprys noted Carlyle Group shares have sold off by over 15% since the announcement of the company's management transition. However, he sees this pullback as a buying opportunity, as he has increased conviction in the company's ability to ramp up management fees in 2018 following a recent Bloomberg article that said its flagship North America buyout fund is approaching a cap of $18.5B, which tops the initial $15B target and would give the company $30B of global corporate private equity buying power when combined with Carlyle's Europe and Asia buyout funds. He maintains an Overweight rating and $28 price target on Carlyle shares.
01/30/18
MSCO
01/30/18
NO CHANGE
MSCO
Morgan Stanley says Ares may be first, Apollo may gain most from C-corp convert
Morgan Stanley analyst Michael Cyprys said he sees an opportunity for Alternative Asset Managers to unlock value by converting to C-corps, as shifting from a partnership structure could help alleviate some tax reporting complexities and expand the universe of eligible investors. He sees Ares Management (ARES) as possibly the first to convert and expects a potential announcement or indications of management's intentions about a conversion when the company reports earnings on February 15. While Ares may be first, Cyprys sees Apollo Global (APO) as potentially being able to unlock the most value from a conversion, with 26% near-term upside possible if the shares re-rate. He sees a less favorable conversion scenario for asset managers with lower taxes and/or greater exposure to performance fees, including KKR (KKR), Carlyle Group (CG) and Blackstone (BX), Cyprys tells investors.
02/14/18
JEFF
02/14/18
UPGRADE
Target $27
JEFF
Buy
Carlyle Group upgraded to Buy from Hold at Jefferies
Jefferies analyst Gerald E. O'Hara upgraded Carlyle Group to Buy and raised his price target for the shares to $27 from $23. The analyst sees an attractive entry point for the shares with the company at the midway point of a $100B fundraising cycle. He believes Carlyle's net accrued performance fees are poised for continued growth with all main drawdown funds currently in carry contribution.

TODAY'S FREE FLY STORIES

RHHBY

Roche

$0.00

(0.00%)

05:24
12/10/18
12/10
05:24
12/10/18
05:24
Hot Stocks
Roche CEO Daniel O'Day to step down, Genentech CEO William Anderson to succeed »

Roche (RHHBY) announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Dec

  • 24

    Dec

  • 18

    Mar

EA

Electronic Arts

$82.57

-1.29 (-1.54%)

05:22
12/10/18
12/10
05:22
12/10/18
05:22
Recommendations
Electronic Arts analyst commentary  »

Electronic Arts price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GILD

Gilead

$68.17

-2.01 (-2.86%)

, RHHBY

Roche

$0.00

(0.00%)

05:21
12/10/18
12/10
05:21
12/10/18
05:21
Hot Stocks
Gilead appoints Roche CEO Daniel O'Day as CEO, chairman »

Gilead Sciences announced…

GILD

Gilead

$68.17

-2.01 (-2.86%)

RHHBY

Roche

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Dec

  • 24

    Dec

  • 18

    Mar

FIVE

Five Below

$95.53

-6.19 (-6.09%)

05:16
12/10/18
12/10
05:16
12/10/18
05:16
Upgrade
Five Below rating change  »

Five Below upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GMXAY

Genmab

$0.00

(0.00%)

05:12
12/10/18
12/10
05:12
12/10/18
05:12
Upgrade
Genmab rating change  »

Genmab upgraded to Buy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

UCBJY

UCB

$0.00

(0.00%)

05:10
12/10/18
12/10
05:10
12/10/18
05:10
Upgrade
UCB rating change  »

UCB upgraded to Buy from…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SWTUY

Swedish Orphan Biovitrum

$0.00

(0.00%)

05:08
12/10/18
12/10
05:08
12/10/18
05:08
Upgrade
Swedish Orphan Biovitrum rating change  »

Swedish Orphan Biovitrum…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MOR

MorphoSys

$27.63

-0.105 (-0.38%)

, JNJ

Johnson & Johnson

$145.38

-0.52 (-0.36%)

05:06
12/10/18
12/10
05:06
12/10/18
05:06
Upgrade
MorphoSys, Johnson & Johnson rating change  »

MorphoSys upgraded to Buy…

MOR

MorphoSys

$27.63

-0.105 (-0.38%)

JNJ

Johnson & Johnson

$145.38

-0.52 (-0.36%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Dec

  • 12

    Dec

SLG

SL Green Realty

$93.32

-2.41 (-2.52%)

05:02
12/10/18
12/10
05:02
12/10/18
05:02
Upgrade
SL Green Realty rating change  »

SL Green Realty upgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CMA

Comerica

$74.07

-1.04 (-1.38%)

04:59
12/10/18
12/10
04:59
12/10/18
04:59
Downgrade
Comerica rating change  »

Comerica downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Jan

PII

Polaris Industries

$88.44

-2.37 (-2.61%)

04:58
12/10/18
12/10
04:58
12/10/18
04:58
Downgrade
Polaris Industries rating change  »

Polaris Industries…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Dec

MPX

Marine Products

$21.59

-0.21 (-0.96%)

04:56
12/10/18
12/10
04:56
12/10/18
04:56
Downgrade
Marine Products rating change  »

Marine Products…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VC

Visteon

$67.58

-4.1 (-5.72%)

04:55
12/10/18
12/10
04:55
12/10/18
04:55
Downgrade
Visteon rating change  »

Visteon downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CORT

Corcept Therapeutics

$13.06

0.01 (0.08%)

04:55
12/10/18
12/10
04:55
12/10/18
04:55
Conference/Events
Corcept Therapeutics management to meet with B.Riley FBR »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Dec

BRG

Bluerock Residential

$9.55

-0.22 (-2.25%)

04:55
12/10/18
12/10
04:55
12/10/18
04:55
Conference/Events
Bluerock Residential management to meet with JMP Securities »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Dec

  • 11

    Dec

GRUB

GrubHub

$76.80

-4.57 (-5.62%)

04:55
12/10/18
12/10
04:55
12/10/18
04:55
Conference/Events
GrubHub management to meet with Oppenheimer »

Meeting to be held in New…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Dec

  • 14

    Dec

HWC

Hancock Whitney

$38.24

0.25 (0.66%)

04:55
12/10/18
12/10
04:55
12/10/18
04:55
Conference/Events
Hancock Whitney management to meet with Sandler O'Neill »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Dec

  • 11

    Dec

KMPR

Kemper

$69.81

-2 (-2.79%)

04:55
12/10/18
12/10
04:55
12/10/18
04:55
Conference/Events
Kemper management to meet with William Blair »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Dec

  • 10

    Dec

NBGIF

National Bank of Greece

$0.00

(0.00%)

04:55
12/10/18
12/10
04:55
12/10/18
04:55
Conference/Events
National Bank of Greece management to meet with Morgan Stanley »

Meeting to be held in New…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Dec

RESI

Front Yard Residential

$9.69

(0.00%)

04:55
12/10/18
12/10
04:55
12/10/18
04:55
Conference/Events
Front Yard Residential management to meet with JMP Securities »

Meeting to be held in the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Dec

PETQ

PetIQ

$31.46

0.09 (0.29%)

04:55
12/10/18
12/10
04:55
12/10/18
04:55
Conference/Events
PetIQ management to meet with William Blair »

Meeting to be held in New…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Dec

AMAG

Amag Pharmaceuticals

$17.53

-0.58 (-3.20%)

04:55
12/10/18
12/10
04:55
12/10/18
04:55
Conference/Events
Amag Pharmaceuticals management to meet with Leerink »

Meeting to be held in San…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Dec

  • 11

    Dec

  • 23

    Mar

ATO

Atmos Energy

$98.80

0.26 (0.26%)

04:55
12/10/18
12/10
04:55
12/10/18
04:55
Conference/Events
Atmos Energy management to meet with Seaport Global »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Dec

  • 11

    Dec

BC

Brunswick

$49.58

-1.56 (-3.05%)

04:55
12/10/18
12/10
04:55
12/10/18
04:55
Conference/Events
Brunswick management to meet with KeyBanc »

Meeting to be held in New…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Dec

CMCO

Columbus McKinnon

$31.52

-0.88 (-2.72%)

04:55
12/10/18
12/10
04:55
12/10/18
04:55
Conference/Events
Columbus McKinnon management to meet with Roth Capital »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Dec

  • 11

    Dec

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.